Coalition for Epidemic Preparedness Innovations

Fondazione Biotecnopolo di Siena is a private, non-profit foundation with a registered office and operations to develop applied research and innovation in the field of biotechnology and life sciences.

Founded in 2014, Micron Biomedical is a clinical-stage biopharmaceutical company based in Atlanta, Georgia. It specializes in developing microneedle patches for vaccines, aiming to enhance protective effects and patient compliance while simplifying administration.

We are developing a global information exchange platform to accelerate the availability of safe and effective medicines.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

Apriori Bio is a health security company dedicated to safeguarding humanity from viral threats. Utilizing an innovative technology platform, the company designs variant-resilient vaccines and develops antibody drugs aimed at addressing both existing and potential viral variants. By providing real-time insights into the landscape of these threats, Apriori Bio enhances preparedness for future outbreaks. Through its focused approach, the company seeks to deliver durable protection against rapidly evolving viruses, contributing to global health security.

BioNTech is a Germany-based biotechnology company focused on developing cancer therapeutics and vaccines for infectious diseases. Its portfolio includes mRNA-based therapies to encode antigens and neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. The company maintains an oncology pipeline and collaborates on vaccines for infectious diseases, including a COVID-19 vaccine developed with Pfizer.

aVaxziPen specializes in developing next-generation vaccines using a needle-free pen applicator technology. This innovative approach protects mRNA and proteins against degradation, eliminating the need for frozen storage and expanding vaccine accessibility, especially in regions with limited cold-chain infrastructure.

Aspen Pharmacare is a global pharmaceutical company that manufactures and supplies branded, generic, and specialty medicines across over 150 countries. Its portfolio includes general anaesthetics, muscle relaxants, anticoagulants, and other therapeutic areas. Aspen also offers contract manufacturing services for active pharmaceutical ingredients and finished dose forms.

SK Bioscience is a South Korean pharmaceutical company focused on the development and manufacturing of vaccines. The company is notable for introducing SKYCellflu, the first cell culture influenza vaccine in Korea, and has since expanded its portfolio to include the SKYCellflu Quadrivalent prefilled syringe and a 13-valent Pneumococcal Conjugate Vaccine. In addition to these licensed products, SK Bioscience is actively engaged in the development of several other vaccines, including a recombinant rotavirus vaccine, a new typhoid conjugate vaccine, and an innovative pneumococcal vaccine, often in collaboration with external partners. The company is dedicated to building a robust infrastructure for continuous vaccine development, positioning itself as a key player in the global vaccine landscape.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Sabin Vaccine Institute is dedicated to enhancing vaccine accessibility and promoting immunization, particularly in low- and middle-income populations that are most vulnerable to infectious diseases. The organization focuses on the development of innovative vaccines aimed at preventing a wide range of diseases, thereby improving public health outcomes. By striving to make vaccines available globally, Sabin Vaccine Institute seeks to benefit individuals and communities, ultimately contributing to better healthcare and disease prevention efforts worldwide.

NEC OncoImmunity AS is a bioinformatics company based in Oslo, Norway, specializing in the development of machine-learning software solutions for personalized cancer immunotherapy. Founded in 2014, the company focuses on addressing critical knowledge gaps in identifying immunogenic neoantigens, which are essential for creating targeted cancer vaccines and cell therapies. Its proprietary platform aids in the selection of patients for these therapies and efficiently identifies optimal neoantigen targets within a clinically actionable timeframe. NEC OncoImmunity's software solutions are designed to support healthcare institutions and research organizations in the discovery of neoantigen-based personalized immunotherapies and biomarkers, enhancing the overall effectiveness of cancer treatment strategies. The company operates as a subsidiary of NEC Corporation, having rebranded from OncoImmunity AS in July 2019.

DIOSynVax is a vaccine antigen design company focused on enhancing vaccine development through innovative technology. The company specializes in digitally designing, immune-optimized selecting, and synthesizing vaccines to improve protection against both emerging and re-emerging pathogens, including influenza, COVID-19, and viral hemorrhagic fevers. By leveraging its advanced technology, DIOSynVax aims to expedite the vaccine development process, ultimately enabling healthcare providers to treat patients more effectively and facilitate quicker recovery from various diseases. Through its efforts, DIOSynVax seeks to make significant advancements in public health by addressing the challenges posed by existing and future viruses.

Clover Biopharmaceuticals, established in 2016, is a global, clinical-stage biotech company dedicated to discovering, developing, and commercializing innovative biologics targeting trimerization-dependent pathways in oncology and autoimmune diseases. The company's proprietary Trimer-Tag© technology platform enables the creation of novel biologics. Additionally, Clover employs its in-house cGMP biomanufacturing capabilities for select biosimilars development.

Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan is a world leader in developing vaccines and technologies against infectious diseases.

MigVax is an Israeli biotechnology company focused on developing vaccines against viral infections in humans. Its innovative approach involves creating vaccines that can be administered orally as dissolvable tablets, stable at room temperature and requiring no healthcare professional for administration.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

Bharat Biotech Ltd. is a biotechnology company based in Hyderabad, India, specializing in the research, development, and manufacture of vaccines and biotherapeutics. Established in 1996, the company offers a diverse range of products, including vaccines such as Revac-B+, a recombinant hepatitis-B vaccine; TYPBAR, a typhoid vaccine; BIOPOLIO, a poliomyelitis vaccine; and INDIRAB, a rabies vaccine. Additionally, Bharat Biotech produces various biotherapeutics, like REGEN-D, a recombinant human epidermal growth factor gel for diabetic foot ulcers and burns, as well as treatments for osteoarthritis and other conditions. The company also provides women's healthcare products and has developed a cell culture H1N1 swine flu vaccine. Bharat Biotech exports its products to several countries, including Kenya, Zambia, and the Philippines, with a focus on creating affordable and effective therapies for neglected diseases.

Novavax is a biotechnology company focused on discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its portfolio centers on nanoparticle vaccines using the Matrix-M adjuvant to elicit strong immune responses, including ResVax for respiratory syncytial virus delivered through maternal immunization and NanoFlu for seasonal influenza in older adults, with both candidates advancing through late-stage clinical trials. The company is advancing additional vaccine programs such as RSV vaccines for older adults and young children, as well as candidates against Ebola and a combined influenza and RSV vaccine. It collaborates with Takeda for NVX-CoV2373, a COVID-19 vaccine candidate, and operates globally via its development and commercialization platform. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax pursues vaccines across multiple stages of clinical development to address urgent health needs.

Inovio Pharmaceuticals specializes in developing DNA medicines to treat, prevent, and protect against diseases caused by human papillomavirus (HPV), cancer, and infectious pathogens. Its proprietary SynCon immunotherapy platform enables robust immune responses via direct intracellular delivery using a smart device. The company's lead candidate, VGX-3100, has shown promise in clinical trials for treating precancerous cervical dysplasia.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Novavax is a biotechnology company focused on discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its portfolio centers on nanoparticle vaccines using the Matrix-M adjuvant to elicit strong immune responses, including ResVax for respiratory syncytial virus delivered through maternal immunization and NanoFlu for seasonal influenza in older adults, with both candidates advancing through late-stage clinical trials. The company is advancing additional vaccine programs such as RSV vaccines for older adults and young children, as well as candidates against Ebola and a combined influenza and RSV vaccine. It collaborates with Takeda for NVX-CoV2373, a COVID-19 vaccine candidate, and operates globally via its development and commercialization platform. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax pursues vaccines across multiple stages of clinical development to address urgent health needs.

Inovio Pharmaceuticals specializes in developing DNA medicines to treat, prevent, and protect against diseases caused by human papillomavirus (HPV), cancer, and infectious pathogens. Its proprietary SynCon immunotherapy platform enables robust immune responses via direct intracellular delivery using a smart device. The company's lead candidate, VGX-3100, has shown promise in clinical trials for treating precancerous cervical dysplasia.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.